Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as Lynk Pharmaceuticals), a clinical stage innovative drug ...

Plant City, Florida - January 09, 2026 - PRESSADVANTAGE - WhiteSands Alcohol & Drug Rehab Plant City has published ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...

The NHS has issued an important message to people taking a common medication for osteoarthritis. According to Arthritis UK, ...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...

A new study published in the journal Science Signaling has found that an immune system protein plays a central role in the ...

Modern medical breakthroughs save lives in ways that feel miraculous, showing how faith and science can work together as ...

More than 10 million people in the UK live with arthritis and many take medication to ease pain, but the NHS warns certain ...